Cargando…

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma

Detalles Bibliográficos
Autores principales:	Fu, Ruiying, Liang, Yuanzheng, Wei, Liqiang, Liu, Xindi, Piao, Yingshi, Wang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129123/ https://www.ncbi.nlm.nih.gov/pubmed/36939235 http://dx.doi.org/10.1097/CM9.0000000000002570

Ejemplares similares

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
por: Liu, Tao, et al.
Publicado: (2018)

P1238: EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA
por: Yuan, X., et al.
Publicado: (2022)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

A novel prognostic model based on ferritin and nomogram‐revised risk index could better stratify patients with extranodal natural killer/T‐cell lymphoma
por: Liu, Xindi, et al.
Publicado: (2023)

Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus
por: Zhao, Qian, et al.
Publicado: (2019)

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
por: Xu, Peng-Peng, et al.
Publicado: (2017)

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine
por: Zhou, Zhiyuan, et al.
Publicado: (2016)

A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China
por: Liang, Rong, et al.
Publicado: (2016)

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase
por: Yang, Jing, et al.
Publicado: (2022)

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution
por: Liang, Yuanzheng, et al.
Publicado: (2023)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
por: Wei, Liqiang, et al.
Publicado: (2020)

Circulating Low Absolute CD4(+) T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy
por: Zhang, Ya-Ping, et al.
Publicado: (2019)

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
por: Liang, J-H, et al.
Publicado: (2017)

Primary Cutaneous Extranodal Natural Killer (NK) T-Cell Lymphoma: A Case Report
por: Zhang, Si, et al.
Publicado: (2023)

Extranodal NK-T-Cell Lymphoma, Nasal-Type Misdiagnosed as Erythema Multiforme with Nasal Fungal Infection
por: Jeong, Soo Hyun, et al.
Publicado: (2022)

Extranodal NK/T cell lymphoma
por: Jeong, Seong Hyun
Publicado: (2020)

Extranodal T- and NK-cell lymphomas
por: de Leval, Laurence, et al.
Publicado: (2022)

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
por: Zhang, Yao, et al.
Publicado: (2021)

An autopsy case of primary extranodal NK/T cell lymphoma (extranodal NK/T-cell lymphoma) of the bile duct
por: Ito, Hiroyuki, et al.
Publicado: (2019)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Laryngeal recurrence of extranodal NK/T cell lymphoma
por: Kumai, Takumi, et al.
Publicado: (2021)

Leukemic presentation of extranodal NK/T‐cell lymphoma
por: Hafeez, Safina, et al.
Publicado: (2021)

P1150: A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA
por: Zhou, Hui, et al.
Publicado: (2023)

LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma
por: Wang, Liang, et al.
Publicado: (2021)

Extranodal NK/T-cell Lymphoma Mimicking Erythema Multiforme
por: Xia, Ying, et al.
Publicado: (2015)

Extranodal NK/T Cell Lymphoma Causing Cardiorespiratory Failure
por: Li, Yiting, et al.
Publicado: (2016)

Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma
por: Hu, Boyu, et al.
Publicado: (2018)

Extranodal NK/T-cell Lymphoma Mimicking Granulomatous Myositis
por: Kawaguchi, Norihiko, et al.
Publicado: (2018)

Molecular pathogenic pathways in extranodal NK/T cell lymphoma
por: de Mel, Sanjay, et al.
Publicado: (2019)

Extranodal NK/T-Cell Lymphoma Mimicking an Infectious Granuloma
por: Suh, Min Song, et al.
Publicado: (2019)

The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma
por: Kim, Hyunsung, et al.
Publicado: (2022)

Extranodal NK/T Cell Lymphoma Mimicking Behçet's Syndrome
por: Wang, Youyang, et al.
Publicado: (2021)

Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
por: Major, Ajay, et al.
Publicado: (2023)

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vfmj11v2d7nku11ule57ngo2ca